secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193125-24-196457
Event type: litigation
Sentiment:  neutral
Materiality: 0.35
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera settles Phase 3 ROMAN trial CRO lawsuit for $975,000
-----------------------------------------------------------

- Settlement with Alira Health Clinical and IQVIA Biotech resolves breach-of-contract and negligence claims.
- CROs paid $975,000 in exchange for mutual releases and termination of contracts with no further obligations.
- Lawsuit stemmed from a 2021 error in statistical programming for the Phase 3 ROMAN trial of avasopasem.
- Galera expects to file a Praecipe to end the litigation by August 8, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312524196457/0001193125-24-196457-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312524196457/d792052d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-196457

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer